nodes	percent_of_prediction	percent_of_DWPC	metapath
Thalidomide—PTGS2—thyroid cancer	0.439	1	CbGaD
Thalidomide—CYP3A5—Sorafenib—thyroid cancer	0.0192	0.31	CbGbCtD
Thalidomide—CYP2C19—Sorafenib—thyroid cancer	0.0155	0.25	CbGbCtD
Thalidomide—CYP1A2—Sorafenib—thyroid cancer	0.0143	0.231	CbGbCtD
Thalidomide—CYP2C9—Sorafenib—thyroid cancer	0.0129	0.208	CbGbCtD
Thalidomide—NFKB1—saliva-secreting gland—thyroid cancer	0.0041	0.0883	CbGeAlD
Thalidomide—FGFR2—neck—thyroid cancer	0.00395	0.085	CbGeAlD
Thalidomide—CRBN—saliva-secreting gland—thyroid cancer	0.00344	0.074	CbGeAlD
Thalidomide—NFKB1—trachea—thyroid cancer	0.00316	0.0681	CbGeAlD
Thalidomide—FGFR2—saliva-secreting gland—thyroid cancer	0.00308	0.0663	CbGeAlD
Thalidomide—TNF—lymph node—thyroid cancer	0.00273	0.0587	CbGeAlD
Thalidomide—CRBN—trachea—thyroid cancer	0.00265	0.0571	CbGeAlD
Thalidomide—NFKB1—thyroid gland—thyroid cancer	0.0025	0.0539	CbGeAlD
Thalidomide—Lenalidomide—PTGS2—thyroid cancer	0.0023	0.518	CrCbGaD
Thalidomide—NFKB1—head—thyroid cancer	0.00222	0.0478	CbGeAlD
Thalidomide—Pomalidomide—PTGS2—thyroid cancer	0.00214	0.482	CrCbGaD
Thalidomide—CRBN—thyroid gland—thyroid cancer	0.0021	0.0451	CbGeAlD
Thalidomide—FGFR2—thyroid gland—thyroid cancer	0.00188	0.0405	CbGeAlD
Thalidomide—CRBN—head—thyroid cancer	0.00186	0.0401	CbGeAlD
Thalidomide—FGFR2—head—thyroid cancer	0.00167	0.0359	CbGeAlD
Thalidomide—NFKB1—lymph node—thyroid cancer	0.00155	0.0335	CbGeAlD
Thalidomide—CRBN—lymph node—thyroid cancer	0.0013	0.028	CbGeAlD
Thalidomide—CYP1A1—trachea—thyroid cancer	0.000859	0.0185	CbGeAlD
Thalidomide—PTGS1—trachea—thyroid cancer	0.000755	0.0163	CbGeAlD
Thalidomide—PTGS2—trachea—thyroid cancer	0.000722	0.0155	CbGeAlD
Thalidomide—CYP1A2—thyroid gland—thyroid cancer	0.000689	0.0148	CbGeAlD
Thalidomide—CYP1A1—thyroid gland—thyroid cancer	0.00068	0.0146	CbGeAlD
Thalidomide—CYP2E1—thyroid gland—thyroid cancer	0.00062	0.0134	CbGeAlD
Thalidomide—CYP1A1—head—thyroid cancer	0.000603	0.013	CbGeAlD
Thalidomide—PTGS1—thyroid gland—thyroid cancer	0.000597	0.0129	CbGeAlD
Thalidomide—CYP2E1—head—thyroid cancer	0.00055	0.0118	CbGeAlD
Thalidomide—PTGS1—head—thyroid cancer	0.00053	0.0114	CbGeAlD
Thalidomide—PTGS2—head—thyroid cancer	0.000506	0.0109	CbGeAlD
Thalidomide—CYP1A1—lymph node—thyroid cancer	0.000422	0.00909	CbGeAlD
Thalidomide—PTGS1—lymph node—thyroid cancer	0.000371	0.00799	CbGeAlD
Thalidomide—PTGS2—lymph node—thyroid cancer	0.000355	0.00764	CbGeAlD
Thalidomide—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.000169	0.000576	CcSEcCtD
Thalidomide—Face oedema—Doxorubicin—thyroid cancer	0.000168	0.000571	CcSEcCtD
Thalidomide—Muscular weakness—Epirubicin—thyroid cancer	0.000165	0.000564	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.000165	0.000564	CcSEcCtD
Thalidomide—Cardiac arrest—Doxorubicin—thyroid cancer	0.000165	0.000563	CcSEcCtD
Thalidomide—Dizziness—Sorafenib—thyroid cancer	0.000165	0.000562	CcSEcCtD
Thalidomide—Mood swings—Doxorubicin—thyroid cancer	0.000164	0.00056	CcSEcCtD
Thalidomide—Abdominal distension—Epirubicin—thyroid cancer	0.000163	0.000556	CcSEcCtD
Thalidomide—Ataxia—Doxorubicin—thyroid cancer	0.000163	0.000556	CcSEcCtD
Thalidomide—Blood creatinine increased—Doxorubicin—thyroid cancer	0.000163	0.000554	CcSEcCtD
Thalidomide—Dysphagia—Epirubicin—thyroid cancer	0.000162	0.000553	CcSEcCtD
Thalidomide—Influenza—Epirubicin—thyroid cancer	0.000162	0.000553	CcSEcCtD
Thalidomide—Dehydration—Doxorubicin—thyroid cancer	0.000161	0.00055	CcSEcCtD
Thalidomide—Eosinophilia—Epirubicin—thyroid cancer	0.000161	0.000547	CcSEcCtD
Thalidomide—Liver function test abnormal—Doxorubicin—thyroid cancer	0.00016	0.000546	CcSEcCtD
Thalidomide—Dry skin—Doxorubicin—thyroid cancer	0.000159	0.000542	CcSEcCtD
Thalidomide—Pancreatitis—Epirubicin—thyroid cancer	0.000159	0.000542	CcSEcCtD
Thalidomide—Vomiting—Sorafenib—thyroid cancer	0.000159	0.000541	CcSEcCtD
Thalidomide—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.000159	0.00054	CcSEcCtD
Thalidomide—Hypokalaemia—Doxorubicin—thyroid cancer	0.000158	0.000538	CcSEcCtD
Thalidomide—Angina pectoris—Epirubicin—thyroid cancer	0.000158	0.000538	CcSEcCtD
Thalidomide—Rash—Sorafenib—thyroid cancer	0.000157	0.000536	CcSEcCtD
Thalidomide—Dermatitis—Sorafenib—thyroid cancer	0.000157	0.000536	CcSEcCtD
Thalidomide—Breast disorder—Doxorubicin—thyroid cancer	0.000157	0.000535	CcSEcCtD
Thalidomide—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000156	0.000533	CcSEcCtD
Thalidomide—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.000156	0.000533	CcSEcCtD
Thalidomide—Headache—Sorafenib—thyroid cancer	0.000156	0.000533	CcSEcCtD
Thalidomide—Bronchitis—Epirubicin—thyroid cancer	0.000156	0.000531	CcSEcCtD
Thalidomide—Pancytopenia—Epirubicin—thyroid cancer	0.000154	0.000525	CcSEcCtD
Thalidomide—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.000153	0.000522	CcSEcCtD
Thalidomide—Muscular weakness—Doxorubicin—thyroid cancer	0.000153	0.000522	CcSEcCtD
Thalidomide—Neutropenia—Epirubicin—thyroid cancer	0.000152	0.000517	CcSEcCtD
Thalidomide—Abdominal distension—Doxorubicin—thyroid cancer	0.000151	0.000515	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.000151	0.000514	CcSEcCtD
Thalidomide—Influenza—Doxorubicin—thyroid cancer	0.00015	0.000511	CcSEcCtD
Thalidomide—Dysphagia—Doxorubicin—thyroid cancer	0.00015	0.000511	CcSEcCtD
Thalidomide—Pollakiuria—Epirubicin—thyroid cancer	0.00015	0.00051	CcSEcCtD
Thalidomide—Eosinophilia—Doxorubicin—thyroid cancer	0.000149	0.000506	CcSEcCtD
Thalidomide—Nausea—Sorafenib—thyroid cancer	0.000148	0.000505	CcSEcCtD
Thalidomide—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000148	0.000504	CcSEcCtD
Thalidomide—Weight increased—Epirubicin—thyroid cancer	0.000148	0.000503	CcSEcCtD
Thalidomide—Pancreatitis—Doxorubicin—thyroid cancer	0.000147	0.000501	CcSEcCtD
Thalidomide—Weight decreased—Epirubicin—thyroid cancer	0.000147	0.0005	CcSEcCtD
Thalidomide—Hyperglycaemia—Epirubicin—thyroid cancer	0.000146	0.000498	CcSEcCtD
Thalidomide—Angina pectoris—Doxorubicin—thyroid cancer	0.000146	0.000498	CcSEcCtD
Thalidomide—Pneumonia—Epirubicin—thyroid cancer	0.000145	0.000496	CcSEcCtD
Thalidomide—Infestation—Epirubicin—thyroid cancer	0.000145	0.000493	CcSEcCtD
Thalidomide—Drowsiness—Epirubicin—thyroid cancer	0.000145	0.000493	CcSEcCtD
Thalidomide—Infestation NOS—Epirubicin—thyroid cancer	0.000145	0.000493	CcSEcCtD
Thalidomide—Bronchitis—Doxorubicin—thyroid cancer	0.000144	0.000492	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000143	0.000488	CcSEcCtD
Thalidomide—Pancytopenia—Doxorubicin—thyroid cancer	0.000142	0.000486	CcSEcCtD
Thalidomide—Renal failure—Epirubicin—thyroid cancer	0.000142	0.000484	CcSEcCtD
Thalidomide—Neuropathy peripheral—Epirubicin—thyroid cancer	0.000142	0.000483	CcSEcCtD
Thalidomide—Stomatitis—Epirubicin—thyroid cancer	0.000141	0.00048	CcSEcCtD
Thalidomide—Conjunctivitis—Epirubicin—thyroid cancer	0.00014	0.000479	CcSEcCtD
Thalidomide—Neutropenia—Doxorubicin—thyroid cancer	0.00014	0.000478	CcSEcCtD
Thalidomide—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.000139	0.000475	CcSEcCtD
Thalidomide—Sweating—Epirubicin—thyroid cancer	0.000139	0.000472	CcSEcCtD
Thalidomide—Pollakiuria—Doxorubicin—thyroid cancer	0.000139	0.000472	CcSEcCtD
Thalidomide—Haematuria—Epirubicin—thyroid cancer	0.000138	0.00047	CcSEcCtD
Thalidomide—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000137	0.000467	CcSEcCtD
Thalidomide—Weight increased—Doxorubicin—thyroid cancer	0.000137	0.000465	CcSEcCtD
Thalidomide—Epistaxis—Epirubicin—thyroid cancer	0.000136	0.000465	CcSEcCtD
Thalidomide—Weight decreased—Doxorubicin—thyroid cancer	0.000136	0.000463	CcSEcCtD
Thalidomide—Sinusitis—Epirubicin—thyroid cancer	0.000136	0.000462	CcSEcCtD
Thalidomide—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000135	0.000461	CcSEcCtD
Thalidomide—Agranulocytosis—Epirubicin—thyroid cancer	0.000135	0.00046	CcSEcCtD
Thalidomide—Pneumonia—Doxorubicin—thyroid cancer	0.000135	0.000459	CcSEcCtD
Thalidomide—Drowsiness—Doxorubicin—thyroid cancer	0.000134	0.000456	CcSEcCtD
Thalidomide—Infestation NOS—Doxorubicin—thyroid cancer	0.000134	0.000456	CcSEcCtD
Thalidomide—Infestation—Doxorubicin—thyroid cancer	0.000134	0.000456	CcSEcCtD
Thalidomide—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000133	0.000452	CcSEcCtD
Thalidomide—Bradycardia—Epirubicin—thyroid cancer	0.000132	0.00045	CcSEcCtD
Thalidomide—Renal failure—Doxorubicin—thyroid cancer	0.000131	0.000448	CcSEcCtD
Thalidomide—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000131	0.000447	CcSEcCtD
Thalidomide—Stomatitis—Doxorubicin—thyroid cancer	0.00013	0.000444	CcSEcCtD
Thalidomide—Rhinitis—Epirubicin—thyroid cancer	0.00013	0.000443	CcSEcCtD
Thalidomide—Conjunctivitis—Doxorubicin—thyroid cancer	0.00013	0.000443	CcSEcCtD
Thalidomide—Hepatitis—Epirubicin—thyroid cancer	0.00013	0.000442	CcSEcCtD
Thalidomide—Hypoaesthesia—Epirubicin—thyroid cancer	0.000129	0.00044	CcSEcCtD
Thalidomide—Pharyngitis—Epirubicin—thyroid cancer	0.000129	0.000439	CcSEcCtD
Thalidomide—Sweating—Doxorubicin—thyroid cancer	0.000128	0.000437	CcSEcCtD
Thalidomide—Urinary tract disorder—Epirubicin—thyroid cancer	0.000128	0.000437	CcSEcCtD
Thalidomide—Oedema peripheral—Epirubicin—thyroid cancer	0.000128	0.000436	CcSEcCtD
Thalidomide—Haematuria—Doxorubicin—thyroid cancer	0.000128	0.000435	CcSEcCtD
Thalidomide—Urethral disorder—Epirubicin—thyroid cancer	0.000127	0.000434	CcSEcCtD
Thalidomide—Epistaxis—Doxorubicin—thyroid cancer	0.000126	0.00043	CcSEcCtD
Thalidomide—Sinusitis—Doxorubicin—thyroid cancer	0.000125	0.000428	CcSEcCtD
Thalidomide—Visual impairment—Epirubicin—thyroid cancer	0.000125	0.000426	CcSEcCtD
Thalidomide—Agranulocytosis—Doxorubicin—thyroid cancer	0.000125	0.000425	CcSEcCtD
Thalidomide—Erythema multiforme—Epirubicin—thyroid cancer	0.000123	0.000418	CcSEcCtD
Thalidomide—Bradycardia—Doxorubicin—thyroid cancer	0.000122	0.000417	CcSEcCtD
Thalidomide—Eye disorder—Epirubicin—thyroid cancer	0.000121	0.000413	CcSEcCtD
Thalidomide—Tinnitus—Epirubicin—thyroid cancer	0.000121	0.000412	CcSEcCtD
Thalidomide—Cardiac disorder—Epirubicin—thyroid cancer	0.00012	0.000411	CcSEcCtD
Thalidomide—Rhinitis—Doxorubicin—thyroid cancer	0.00012	0.00041	CcSEcCtD
Thalidomide—Hepatitis—Doxorubicin—thyroid cancer	0.00012	0.000409	CcSEcCtD
Thalidomide—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000119	0.000407	CcSEcCtD
Thalidomide—Pharyngitis—Doxorubicin—thyroid cancer	0.000119	0.000406	CcSEcCtD
Thalidomide—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000119	0.000404	CcSEcCtD
Thalidomide—Oedema peripheral—Doxorubicin—thyroid cancer	0.000118	0.000403	CcSEcCtD
Thalidomide—Angiopathy—Epirubicin—thyroid cancer	0.000118	0.000401	CcSEcCtD
Thalidomide—Urethral disorder—Doxorubicin—thyroid cancer	0.000118	0.000401	CcSEcCtD
Thalidomide—Immune system disorder—Epirubicin—thyroid cancer	0.000117	0.0004	CcSEcCtD
Thalidomide—Mediastinal disorder—Epirubicin—thyroid cancer	0.000117	0.000399	CcSEcCtD
Thalidomide—Chills—Epirubicin—thyroid cancer	0.000116	0.000397	CcSEcCtD
Thalidomide—Arrhythmia—Epirubicin—thyroid cancer	0.000116	0.000395	CcSEcCtD
Thalidomide—Visual impairment—Doxorubicin—thyroid cancer	0.000116	0.000394	CcSEcCtD
Thalidomide—Alopecia—Epirubicin—thyroid cancer	0.000115	0.000391	CcSEcCtD
Thalidomide—Mental disorder—Epirubicin—thyroid cancer	0.000114	0.000388	CcSEcCtD
Thalidomide—Erythema multiforme—Doxorubicin—thyroid cancer	0.000114	0.000387	CcSEcCtD
Thalidomide—Malnutrition—Epirubicin—thyroid cancer	0.000113	0.000385	CcSEcCtD
Thalidomide—Eye disorder—Doxorubicin—thyroid cancer	0.000112	0.000382	CcSEcCtD
Thalidomide—Tinnitus—Doxorubicin—thyroid cancer	0.000112	0.000382	CcSEcCtD
Thalidomide—Cardiac disorder—Doxorubicin—thyroid cancer	0.000111	0.00038	CcSEcCtD
Thalidomide—Flatulence—Epirubicin—thyroid cancer	0.000111	0.000379	CcSEcCtD
Thalidomide—Tension—Epirubicin—thyroid cancer	0.000111	0.000378	CcSEcCtD
Thalidomide—Dysgeusia—Epirubicin—thyroid cancer	0.000111	0.000377	CcSEcCtD
Thalidomide—Nervousness—Epirubicin—thyroid cancer	0.00011	0.000374	CcSEcCtD
Thalidomide—Back pain—Epirubicin—thyroid cancer	0.000109	0.000372	CcSEcCtD
Thalidomide—Angiopathy—Doxorubicin—thyroid cancer	0.000109	0.000371	CcSEcCtD
Thalidomide—Muscle spasms—Epirubicin—thyroid cancer	0.000109	0.00037	CcSEcCtD
Thalidomide—Immune system disorder—Doxorubicin—thyroid cancer	0.000108	0.00037	CcSEcCtD
Thalidomide—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000108	0.000369	CcSEcCtD
Thalidomide—Chills—Doxorubicin—thyroid cancer	0.000108	0.000367	CcSEcCtD
Thalidomide—Arrhythmia—Doxorubicin—thyroid cancer	0.000107	0.000366	CcSEcCtD
Thalidomide—Vision blurred—Epirubicin—thyroid cancer	0.000106	0.000363	CcSEcCtD
Thalidomide—Alopecia—Doxorubicin—thyroid cancer	0.000106	0.000362	CcSEcCtD
Thalidomide—Mental disorder—Doxorubicin—thyroid cancer	0.000105	0.000359	CcSEcCtD
Thalidomide—Ill-defined disorder—Epirubicin—thyroid cancer	0.000105	0.000357	CcSEcCtD
Thalidomide—Malnutrition—Doxorubicin—thyroid cancer	0.000105	0.000356	CcSEcCtD
Thalidomide—Anaemia—Epirubicin—thyroid cancer	0.000104	0.000356	CcSEcCtD
Thalidomide—Agitation—Epirubicin—thyroid cancer	0.000104	0.000354	CcSEcCtD
Thalidomide—Flatulence—Doxorubicin—thyroid cancer	0.000103	0.000351	CcSEcCtD
Thalidomide—Tension—Doxorubicin—thyroid cancer	0.000103	0.00035	CcSEcCtD
Thalidomide—Dysgeusia—Doxorubicin—thyroid cancer	0.000102	0.000349	CcSEcCtD
Thalidomide—Malaise—Epirubicin—thyroid cancer	0.000102	0.000347	CcSEcCtD
Thalidomide—Nervousness—Doxorubicin—thyroid cancer	0.000102	0.000346	CcSEcCtD
Thalidomide—Vertigo—Epirubicin—thyroid cancer	0.000101	0.000346	CcSEcCtD
Thalidomide—Syncope—Epirubicin—thyroid cancer	0.000101	0.000345	CcSEcCtD
Thalidomide—Leukopenia—Epirubicin—thyroid cancer	0.000101	0.000345	CcSEcCtD
Thalidomide—Back pain—Doxorubicin—thyroid cancer	0.000101	0.000345	CcSEcCtD
Thalidomide—Muscle spasms—Doxorubicin—thyroid cancer	0.0001	0.000343	CcSEcCtD
Thalidomide—Palpitations—Epirubicin—thyroid cancer	9.98e-05	0.00034	CcSEcCtD
Thalidomide—Loss of consciousness—Epirubicin—thyroid cancer	9.93e-05	0.000338	CcSEcCtD
Thalidomide—Cough—Epirubicin—thyroid cancer	9.86e-05	0.000336	CcSEcCtD
Thalidomide—Vision blurred—Doxorubicin—thyroid cancer	9.85e-05	0.000336	CcSEcCtD
Thalidomide—Convulsion—Epirubicin—thyroid cancer	9.79e-05	0.000334	CcSEcCtD
Thalidomide—Hypertension—Epirubicin—thyroid cancer	9.75e-05	0.000332	CcSEcCtD
Thalidomide—Ill-defined disorder—Doxorubicin—thyroid cancer	9.7e-05	0.000331	CcSEcCtD
Thalidomide—Anaemia—Doxorubicin—thyroid cancer	9.66e-05	0.000329	CcSEcCtD
Thalidomide—Chest pain—Epirubicin—thyroid cancer	9.62e-05	0.000328	CcSEcCtD
Thalidomide—Myalgia—Epirubicin—thyroid cancer	9.62e-05	0.000328	CcSEcCtD
Thalidomide—Arthralgia—Epirubicin—thyroid cancer	9.62e-05	0.000328	CcSEcCtD
Thalidomide—Agitation—Doxorubicin—thyroid cancer	9.6e-05	0.000327	CcSEcCtD
Thalidomide—Anxiety—Epirubicin—thyroid cancer	9.58e-05	0.000327	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	9.55e-05	0.000326	CcSEcCtD
Thalidomide—Discomfort—Epirubicin—thyroid cancer	9.5e-05	0.000324	CcSEcCtD
Thalidomide—Malaise—Doxorubicin—thyroid cancer	9.43e-05	0.000321	CcSEcCtD
Thalidomide—Dry mouth—Epirubicin—thyroid cancer	9.4e-05	0.000321	CcSEcCtD
Thalidomide—Vertigo—Doxorubicin—thyroid cancer	9.39e-05	0.00032	CcSEcCtD
Thalidomide—Syncope—Doxorubicin—thyroid cancer	9.37e-05	0.00032	CcSEcCtD
Thalidomide—Leukopenia—Doxorubicin—thyroid cancer	9.36e-05	0.000319	CcSEcCtD
Thalidomide—Confusional state—Epirubicin—thyroid cancer	9.3e-05	0.000317	CcSEcCtD
Thalidomide—Palpitations—Doxorubicin—thyroid cancer	9.24e-05	0.000315	CcSEcCtD
Thalidomide—Oedema—Epirubicin—thyroid cancer	9.22e-05	0.000314	CcSEcCtD
Thalidomide—Loss of consciousness—Doxorubicin—thyroid cancer	9.19e-05	0.000313	CcSEcCtD
Thalidomide—Infection—Epirubicin—thyroid cancer	9.16e-05	0.000312	CcSEcCtD
Thalidomide—Cough—Doxorubicin—thyroid cancer	9.12e-05	0.000311	CcSEcCtD
Thalidomide—Shock—Epirubicin—thyroid cancer	9.07e-05	0.000309	CcSEcCtD
Thalidomide—Convulsion—Doxorubicin—thyroid cancer	9.06e-05	0.000309	CcSEcCtD
Thalidomide—Nervous system disorder—Epirubicin—thyroid cancer	9.04e-05	0.000308	CcSEcCtD
Thalidomide—Thrombocytopenia—Epirubicin—thyroid cancer	9.03e-05	0.000308	CcSEcCtD
Thalidomide—Hypertension—Doxorubicin—thyroid cancer	9.02e-05	0.000308	CcSEcCtD
Thalidomide—Tachycardia—Epirubicin—thyroid cancer	9e-05	0.000307	CcSEcCtD
Thalidomide—Skin disorder—Epirubicin—thyroid cancer	8.95e-05	0.000305	CcSEcCtD
Thalidomide—Hyperhidrosis—Epirubicin—thyroid cancer	8.91e-05	0.000304	CcSEcCtD
Thalidomide—Arthralgia—Doxorubicin—thyroid cancer	8.9e-05	0.000303	CcSEcCtD
Thalidomide—Myalgia—Doxorubicin—thyroid cancer	8.9e-05	0.000303	CcSEcCtD
Thalidomide—Chest pain—Doxorubicin—thyroid cancer	8.9e-05	0.000303	CcSEcCtD
Thalidomide—Anxiety—Doxorubicin—thyroid cancer	8.87e-05	0.000302	CcSEcCtD
Thalidomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	8.84e-05	0.000301	CcSEcCtD
Thalidomide—Discomfort—Doxorubicin—thyroid cancer	8.79e-05	0.0003	CcSEcCtD
Thalidomide—Anorexia—Epirubicin—thyroid cancer	8.79e-05	0.0003	CcSEcCtD
Thalidomide—Dry mouth—Doxorubicin—thyroid cancer	8.7e-05	0.000297	CcSEcCtD
Thalidomide—Hypotension—Epirubicin—thyroid cancer	8.61e-05	0.000294	CcSEcCtD
Thalidomide—Confusional state—Doxorubicin—thyroid cancer	8.6e-05	0.000293	CcSEcCtD
Thalidomide—Oedema—Doxorubicin—thyroid cancer	8.53e-05	0.000291	CcSEcCtD
Thalidomide—Infection—Doxorubicin—thyroid cancer	8.47e-05	0.000289	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Epirubicin—thyroid cancer	8.4e-05	0.000286	CcSEcCtD
Thalidomide—Shock—Doxorubicin—thyroid cancer	8.39e-05	0.000286	CcSEcCtD
Thalidomide—Nervous system disorder—Doxorubicin—thyroid cancer	8.36e-05	0.000285	CcSEcCtD
Thalidomide—Thrombocytopenia—Doxorubicin—thyroid cancer	8.35e-05	0.000285	CcSEcCtD
Thalidomide—Insomnia—Epirubicin—thyroid cancer	8.34e-05	0.000284	CcSEcCtD
Thalidomide—Tachycardia—Doxorubicin—thyroid cancer	8.32e-05	0.000284	CcSEcCtD
Thalidomide—Skin disorder—Doxorubicin—thyroid cancer	8.29e-05	0.000282	CcSEcCtD
Thalidomide—Paraesthesia—Epirubicin—thyroid cancer	8.28e-05	0.000282	CcSEcCtD
Thalidomide—Hyperhidrosis—Doxorubicin—thyroid cancer	8.25e-05	0.000281	CcSEcCtD
Thalidomide—Dyspnoea—Epirubicin—thyroid cancer	8.22e-05	0.00028	CcSEcCtD
Thalidomide—Somnolence—Epirubicin—thyroid cancer	8.2e-05	0.000279	CcSEcCtD
Thalidomide—Anorexia—Doxorubicin—thyroid cancer	8.13e-05	0.000277	CcSEcCtD
Thalidomide—Dyspepsia—Epirubicin—thyroid cancer	8.11e-05	0.000277	CcSEcCtD
Thalidomide—Decreased appetite—Epirubicin—thyroid cancer	8.01e-05	0.000273	CcSEcCtD
Thalidomide—Hypotension—Doxorubicin—thyroid cancer	7.97e-05	0.000272	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Epirubicin—thyroid cancer	7.96e-05	0.000271	CcSEcCtD
Thalidomide—Fatigue—Epirubicin—thyroid cancer	7.95e-05	0.000271	CcSEcCtD
Thalidomide—Pain—Epirubicin—thyroid cancer	7.88e-05	0.000269	CcSEcCtD
Thalidomide—Constipation—Epirubicin—thyroid cancer	7.88e-05	0.000269	CcSEcCtD
Thalidomide—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	7.77e-05	0.000265	CcSEcCtD
Thalidomide—Insomnia—Doxorubicin—thyroid cancer	7.71e-05	0.000263	CcSEcCtD
Thalidomide—Paraesthesia—Doxorubicin—thyroid cancer	7.66e-05	0.000261	CcSEcCtD
Thalidomide—Dyspnoea—Doxorubicin—thyroid cancer	7.6e-05	0.000259	CcSEcCtD
Thalidomide—Feeling abnormal—Epirubicin—thyroid cancer	7.6e-05	0.000259	CcSEcCtD
Thalidomide—Somnolence—Doxorubicin—thyroid cancer	7.58e-05	0.000258	CcSEcCtD
Thalidomide—Gastrointestinal pain—Epirubicin—thyroid cancer	7.54e-05	0.000257	CcSEcCtD
Thalidomide—Dyspepsia—Doxorubicin—thyroid cancer	7.51e-05	0.000256	CcSEcCtD
Thalidomide—Decreased appetite—Doxorubicin—thyroid cancer	7.41e-05	0.000253	CcSEcCtD
Thalidomide—Gastrointestinal disorder—Doxorubicin—thyroid cancer	7.36e-05	0.000251	CcSEcCtD
Thalidomide—Fatigue—Doxorubicin—thyroid cancer	7.35e-05	0.000251	CcSEcCtD
Thalidomide—Urticaria—Epirubicin—thyroid cancer	7.32e-05	0.00025	CcSEcCtD
Thalidomide—Pain—Doxorubicin—thyroid cancer	7.29e-05	0.000249	CcSEcCtD
Thalidomide—Constipation—Doxorubicin—thyroid cancer	7.29e-05	0.000249	CcSEcCtD
Thalidomide—Abdominal pain—Epirubicin—thyroid cancer	7.29e-05	0.000248	CcSEcCtD
Thalidomide—Body temperature increased—Epirubicin—thyroid cancer	7.29e-05	0.000248	CcSEcCtD
Thalidomide—Feeling abnormal—Doxorubicin—thyroid cancer	7.03e-05	0.00024	CcSEcCtD
Thalidomide—Gastrointestinal pain—Doxorubicin—thyroid cancer	6.98e-05	0.000238	CcSEcCtD
Thalidomide—Hypersensitivity—Epirubicin—thyroid cancer	6.79e-05	0.000232	CcSEcCtD
Thalidomide—Urticaria—Doxorubicin—thyroid cancer	6.78e-05	0.000231	CcSEcCtD
Thalidomide—Body temperature increased—Doxorubicin—thyroid cancer	6.74e-05	0.00023	CcSEcCtD
Thalidomide—Abdominal pain—Doxorubicin—thyroid cancer	6.74e-05	0.00023	CcSEcCtD
Thalidomide—Asthenia—Epirubicin—thyroid cancer	6.61e-05	0.000225	CcSEcCtD
Thalidomide—Pruritus—Epirubicin—thyroid cancer	6.52e-05	0.000222	CcSEcCtD
Thalidomide—Diarrhoea—Epirubicin—thyroid cancer	6.31e-05	0.000215	CcSEcCtD
Thalidomide—Hypersensitivity—Doxorubicin—thyroid cancer	6.28e-05	0.000214	CcSEcCtD
Thalidomide—Asthenia—Doxorubicin—thyroid cancer	6.12e-05	0.000209	CcSEcCtD
Thalidomide—Dizziness—Epirubicin—thyroid cancer	6.1e-05	0.000208	CcSEcCtD
Thalidomide—CYP1A1—Metabolism—CHST14—thyroid cancer	6.04e-05	0.000391	CbGpPWpGaD
Thalidomide—Pruritus—Doxorubicin—thyroid cancer	6.03e-05	0.000206	CcSEcCtD
Thalidomide—TNF—Apoptosis—TP53—thyroid cancer	6.02e-05	0.000389	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—NRAS—thyroid cancer	6e-05	0.000388	CbGpPWpGaD
Thalidomide—NFKB1—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	6e-05	0.000388	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—HRAS—thyroid cancer	5.97e-05	0.000386	CbGpPWpGaD
Thalidomide—FGFR2—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thyroid cancer	5.96e-05	0.000386	CbGpPWpGaD
Thalidomide—Vomiting—Epirubicin—thyroid cancer	5.86e-05	0.0002	CcSEcCtD
Thalidomide—NFKB1—Immune System—CDK1—thyroid cancer	5.86e-05	0.000379	CbGpPWpGaD
Thalidomide—Diarrhoea—Doxorubicin—thyroid cancer	5.84e-05	0.000199	CcSEcCtD
Thalidomide—Rash—Epirubicin—thyroid cancer	5.81e-05	0.000198	CcSEcCtD
Thalidomide—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	5.81e-05	0.000376	CbGpPWpGaD
Thalidomide—Dermatitis—Epirubicin—thyroid cancer	5.81e-05	0.000198	CcSEcCtD
Thalidomide—Headache—Epirubicin—thyroid cancer	5.78e-05	0.000197	CcSEcCtD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.73e-05	0.000371	CbGpPWpGaD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—HRAS—thyroid cancer	5.71e-05	0.000369	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by FGFR in disease—AKT1—thyroid cancer	5.69e-05	0.000368	CbGpPWpGaD
Thalidomide—FGFR2—DAP12 interactions—AKT1—thyroid cancer	5.69e-05	0.000368	CbGpPWpGaD
Thalidomide—FGFR2—Fc epsilon receptor (FCERI) signaling—AKT1—thyroid cancer	5.69e-05	0.000368	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CALCA—thyroid cancer	5.67e-05	0.000367	CbGpPWpGaD
Thalidomide—NFKB1—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	5.64e-05	0.000365	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—TP53—thyroid cancer	5.64e-05	0.000365	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR—AKT1—thyroid cancer	5.64e-05	0.000365	CbGpPWpGaD
Thalidomide—Dizziness—Doxorubicin—thyroid cancer	5.64e-05	0.000192	CcSEcCtD
Thalidomide—CYP2C9—Metabolism—MINPP1—thyroid cancer	5.64e-05	0.000365	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—IFNA2—thyroid cancer	5.63e-05	0.000365	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	5.6e-05	0.000363	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by EGFR in Cancer—AKT1—thyroid cancer	5.59e-05	0.000362	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TSHR—thyroid cancer	5.59e-05	0.000362	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by PDGF—AKT1—thyroid cancer	5.57e-05	0.00036	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—CDK1—thyroid cancer	5.56e-05	0.00036	CbGpPWpGaD
Thalidomide—NFKB1—B Cell Activation—AKT1—thyroid cancer	5.55e-05	0.000359	CbGpPWpGaD
Thalidomide—TNF—Regulation of toll-like receptor signaling pathway—AKT1—thyroid cancer	5.55e-05	0.000359	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—KRAS—thyroid cancer	5.54e-05	0.000358	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PRKAR1A—thyroid cancer	5.5e-05	0.000356	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—HPGD—thyroid cancer	5.48e-05	0.000355	CbGpPWpGaD
Thalidomide—Nausea—Epirubicin—thyroid cancer	5.48e-05	0.000187	CcSEcCtD
Thalidomide—NFKB1—Signaling by NGF—KRAS—thyroid cancer	5.44e-05	0.000352	CbGpPWpGaD
Thalidomide—Vomiting—Doxorubicin—thyroid cancer	5.42e-05	0.000185	CcSEcCtD
Thalidomide—Rash—Doxorubicin—thyroid cancer	5.38e-05	0.000183	CcSEcCtD
Thalidomide—Dermatitis—Doxorubicin—thyroid cancer	5.37e-05	0.000183	CcSEcCtD
Thalidomide—FGFR2—Immune System—IFNA2—thyroid cancer	5.35e-05	0.000346	CbGpPWpGaD
Thalidomide—Headache—Doxorubicin—thyroid cancer	5.34e-05	0.000182	CcSEcCtD
Thalidomide—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	5.32e-05	0.000345	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TSHR—thyroid cancer	5.3e-05	0.000343	CbGpPWpGaD
Thalidomide—FGFR2—B Cell Activation—AKT1—thyroid cancer	5.27e-05	0.000341	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—NDUFA13—thyroid cancer	5.26e-05	0.00034	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—MEN1—thyroid cancer	5.26e-05	0.00034	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PRKAR1A—thyroid cancer	5.22e-05	0.000338	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—KRAS—thyroid cancer	5.17e-05	0.000334	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—HPGD—thyroid cancer	5.16e-05	0.000334	CbGpPWpGaD
Thalidomide—NFKB1—Cellular responses to stress—TP53—thyroid cancer	5.16e-05	0.000334	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—HPGD—thyroid cancer	5.15e-05	0.000333	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TCF7L1—thyroid cancer	5.14e-05	0.000333	CbGpPWpGaD
Thalidomide—FGFR2—Disease—CDK1—thyroid cancer	5.13e-05	0.000332	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	5.09e-05	0.00033	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—PPARG—thyroid cancer	5.09e-05	0.000329	CbGpPWpGaD
Thalidomide—TNF—Apoptosis—AKT1—thyroid cancer	5.08e-05	0.000329	CbGpPWpGaD
Thalidomide—Nausea—Doxorubicin—thyroid cancer	5.07e-05	0.000173	CcSEcCtD
Thalidomide—FGFR2—NGF signalling via TRKA from the plasma membrane—AKT1—thyroid cancer	5.04e-05	0.000326	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—MEN1—thyroid cancer	4.99e-05	0.000323	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—CHST14—thyroid cancer	4.94e-05	0.00032	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—HPGD—thyroid cancer	4.87e-05	0.000315	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—MINPP1—thyroid cancer	4.82e-05	0.000312	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—NDUFA13—thyroid cancer	4.79e-05	0.00031	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	4.78e-05	0.000309	CbGpPWpGaD
Thalidomide—TNF—MAPK Signaling Pathway—AKT1—thyroid cancer	4.77e-05	0.000308	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTCH1—thyroid cancer	4.75e-05	0.000308	CbGpPWpGaD
Thalidomide—NFKB1—Cytokine Signaling in Immune system—HRAS—thyroid cancer	4.71e-05	0.000305	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRG1—thyroid cancer	4.7e-05	0.000304	CbGpPWpGaD
Thalidomide—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	4.63e-05	0.0003	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—HRAS—thyroid cancer	4.63e-05	0.0003	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	4.61e-05	0.000299	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTCH1—thyroid cancer	4.51e-05	0.000292	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—CHST14—thyroid cancer	4.51e-05	0.000292	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRG1—thyroid cancer	4.46e-05	0.000289	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.45e-05	0.000288	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—HRAS—thyroid cancer	4.39e-05	0.000284	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—SST—thyroid cancer	4.35e-05	0.000281	CbGpPWpGaD
Thalidomide—TNF—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	4.3e-05	0.000278	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CALCA—thyroid cancer	4.18e-05	0.000271	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—SST—thyroid cancer	4.12e-05	0.000267	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRG1—thyroid cancer	4.12e-05	0.000267	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—NDUFA13—thyroid cancer	4.1e-05	0.000265	CbGpPWpGaD
Thalidomide—NFKB1—Signaling by NGF—AKT1—thyroid cancer	4.09e-05	0.000264	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—NRAS—thyroid cancer	4.09e-05	0.000264	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—PTEN—thyroid cancer	4.04e-05	0.000262	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—HPGD—thyroid cancer	3.98e-05	0.000258	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CALCA—thyroid cancer	3.97e-05	0.000257	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—TPR—thyroid cancer	3.97e-05	0.000257	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.95e-05	0.000256	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PRKAR1A—thyroid cancer	3.9e-05	0.000253	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—PTEN—thyroid cancer	3.88e-05	0.000251	CbGpPWpGaD
Thalidomide—FGFR2—Signaling by NGF—AKT1—thyroid cancer	3.88e-05	0.000251	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—CHST14—thyroid cancer	3.85e-05	0.000249	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—PTEN—thyroid cancer	3.84e-05	0.000248	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CDK1—thyroid cancer	3.79e-05	0.000245	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TPR—thyroid cancer	3.76e-05	0.000243	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PRKAR1A—thyroid cancer	3.7e-05	0.000239	CbGpPWpGaD
Thalidomide—FGFR2—Disease—TERT—thyroid cancer	3.7e-05	0.000239	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—PTEN—thyroid cancer	3.68e-05	0.000238	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—HPGD—thyroid cancer	3.63e-05	0.000235	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—NRAS—thyroid cancer	3.61e-05	0.000234	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CDK1—thyroid cancer	3.59e-05	0.000233	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	3.54e-05	0.000229	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	3.54e-05	0.000229	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HIF1A—thyroid cancer	3.54e-05	0.000229	CbGpPWpGaD
Thalidomide—PTGS2—Disease—MEN1—thyroid cancer	3.54e-05	0.000229	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—KRAS—thyroid cancer	3.52e-05	0.000228	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—NRAS—thyroid cancer	3.46e-05	0.000224	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—NRAS—thyroid cancer	3.42e-05	0.000222	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—NRAS—thyroid cancer	3.29e-05	0.000213	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	3.23e-05	0.000209	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—TPR—thyroid cancer	3.15e-05	0.000204	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	3.15e-05	0.000204	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—NRAS—thyroid cancer	3.11e-05	0.000201	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—KRAS—thyroid cancer	3.11e-05	0.000201	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—HPGD—thyroid cancer	3.1e-05	0.000201	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PRKAR1A—thyroid cancer	3.1e-05	0.000201	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRG1—thyroid cancer	3.04e-05	0.000197	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—HRAS—thyroid cancer	2.99e-05	0.000193	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—KRAS—thyroid cancer	2.98e-05	0.000193	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—SLC5A5—thyroid cancer	2.97e-05	0.000192	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—TPR—thyroid cancer	2.97e-05	0.000192	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—TPR—thyroid cancer	2.96e-05	0.000192	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—KRAS—thyroid cancer	2.95e-05	0.000191	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.95e-05	0.000191	CbGpPWpGaD
Thalidomide—FGFR2—Disease—BRAF—thyroid cancer	2.93e-05	0.00019	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PRKAR1A—thyroid cancer	2.92e-05	0.000189	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PRKAR1A—thyroid cancer	2.91e-05	0.000188	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRG1—thyroid cancer	2.88e-05	0.000187	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—KRAS—thyroid cancer	2.83e-05	0.000183	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CALCA—thyroid cancer	2.82e-05	0.000182	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.81e-05	0.000182	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—TPR—thyroid cancer	2.8e-05	0.000181	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.78e-05	0.00018	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PRKAR1A—thyroid cancer	2.75e-05	0.000178	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TERT—thyroid cancer	2.73e-05	0.000177	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—KRAS—thyroid cancer	2.68e-05	0.000173	CbGpPWpGaD
Thalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	2.66e-05	0.000172	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—HRAS—thyroid cancer	2.64e-05	0.000171	CbGpPWpGaD
Thalidomide—NFKB1—Developmental Biology—AKT1—thyroid cancer	2.64e-05	0.000171	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HIF1A—thyroid cancer	2.61e-05	0.000169	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TERT—thyroid cancer	2.59e-05	0.000168	CbGpPWpGaD
Thalidomide—PTGS2—Disease—CDK1—thyroid cancer	2.55e-05	0.000165	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—HRAS—thyroid cancer	2.53e-05	0.000164	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	2.52e-05	0.000163	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—HRAS—thyroid cancer	2.5e-05	0.000162	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—RXRA—thyroid cancer	2.5e-05	0.000162	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.49e-05	0.000161	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HIF1A—thyroid cancer	2.48e-05	0.00016	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.43e-05	0.000157	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—HRAS—thyroid cancer	2.41e-05	0.000156	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTGS2—thyroid cancer	2.37e-05	0.000153	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—SLC5A5—thyroid cancer	2.36e-05	0.000153	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—PTEN—thyroid cancer	2.36e-05	0.000152	CbGpPWpGaD
Thalidomide—NFKB1—Innate Immune System—AKT1—thyroid cancer	2.33e-05	0.000151	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—TPR—thyroid cancer	2.29e-05	0.000148	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—HRAS—thyroid cancer	2.28e-05	0.000147	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PRKAR1A—thyroid cancer	2.25e-05	0.000146	CbGpPWpGaD
Thalidomide—NFKB1—Adaptive Immune System—AKT1—thyroid cancer	2.24e-05	0.000145	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—PTEN—thyroid cancer	2.23e-05	0.000145	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—SLC5A5—thyroid cancer	2.22e-05	0.000144	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—SLC5A5—thyroid cancer	2.22e-05	0.000143	CbGpPWpGaD
Thalidomide—FGFR2—Innate Immune System—AKT1—thyroid cancer	2.21e-05	0.000143	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—BRAF—thyroid cancer	2.16e-05	0.00014	CbGpPWpGaD
Thalidomide—FGFR2—Adaptive Immune System—AKT1—thyroid cancer	2.12e-05	0.000137	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—NRAS—thyroid cancer	2.1e-05	0.000136	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—SLC5A5—thyroid cancer	2.09e-05	0.000135	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—TPR—thyroid cancer	2.09e-05	0.000135	CbGpPWpGaD
Thalidomide—FGFR2—Disease—PTEN—thyroid cancer	2.06e-05	0.000134	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	2.05e-05	0.000133	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—BRAF—thyroid cancer	2.05e-05	0.000133	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRG1—thyroid cancer	2.05e-05	0.000132	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.04e-05	0.000132	CbGpPWpGaD
Thalidomide—TNF—Developmental Biology—AKT1—thyroid cancer	2.01e-05	0.00013	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—NRAS—thyroid cancer	1.99e-05	0.000129	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—RXRA—thyroid cancer	1.98e-05	0.000128	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.96e-05	0.000127	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.93e-05	0.000125	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—RXRA—thyroid cancer	1.87e-05	0.000121	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—RXRA—thyroid cancer	1.86e-05	0.00012	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.86e-05	0.00012	CbGpPWpGaD
Thalidomide—FGFR2—Disease—NRAS—thyroid cancer	1.84e-05	0.000119	CbGpPWpGaD
Thalidomide—PTGS2—Disease—TERT—thyroid cancer	1.84e-05	0.000119	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—KRAS—thyroid cancer	1.81e-05	0.000117	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—TPR—thyroid cancer	1.78e-05	0.000115	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—RXRA—thyroid cancer	1.76e-05	0.000114	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HIF1A—thyroid cancer	1.76e-05	0.000114	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PRKAR1A—thyroid cancer	1.75e-05	0.000113	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—KRAS—thyroid cancer	1.72e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—SLC5A5—thyroid cancer	1.71e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.71e-05	0.000111	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.6e-05	0.000104	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	1.59e-05	0.000103	CbGpPWpGaD
Thalidomide—FGFR2—Disease—KRAS—thyroid cancer	1.58e-05	0.000103	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—CCND1—thyroid cancer	1.58e-05	0.000102	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PPARG—thyroid cancer	1.58e-05	0.000102	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—SLC5A5—thyroid cancer	1.56e-05	0.000101	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—HRAS—thyroid cancer	1.54e-05	9.95e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—PTEN—thyroid cancer	1.52e-05	9.86e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—CCND1—thyroid cancer	1.5e-05	9.69e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.46e-05	9.47e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—HRAS—thyroid cancer	1.46e-05	9.44e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—BRAF—thyroid cancer	1.45e-05	9.41e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—PTEN—thyroid cancer	1.44e-05	9.35e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—RXRA—thyroid cancer	1.44e-05	9.31e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.4e-05	9.06e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—NRAS—thyroid cancer	1.36e-05	8.79e-05	CbGpPWpGaD
Thalidomide—NFKB1—Immune System—AKT1—thyroid cancer	1.36e-05	8.79e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—HRAS—thyroid cancer	1.35e-05	8.72e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—SLC5A5—thyroid cancer	1.33e-05	8.64e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—RXRA—thyroid cancer	1.31e-05	8.49e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—NRAS—thyroid cancer	1.29e-05	8.34e-05	CbGpPWpGaD
Thalidomide—FGFR2—Immune System—AKT1—thyroid cancer	1.29e-05	8.34e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.28e-05	8.26e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PPARG—thyroid cancer	1.25e-05	8.1e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	1.25e-05	8.09e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTGS2—thyroid cancer	1.24e-05	8.02e-05	CbGpPWpGaD
Thalidomide—FGFR2—Disease—AKT1—thyroid cancer	1.19e-05	7.7e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PPARG—thyroid cancer	1.18e-05	7.62e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PPARG—thyroid cancer	1.18e-05	7.61e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—KRAS—thyroid cancer	1.17e-05	7.57e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—RXRA—thyroid cancer	1.12e-05	7.26e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PPARG—thyroid cancer	1.11e-05	7.19e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—KRAS—thyroid cancer	1.11e-05	7.18e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.09e-05	7.06e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—PTEN—thyroid cancer	1.08e-05	7e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—TP53—thyroid cancer	1.04e-05	6.73e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—PTEN—thyroid cancer	1.02e-05	6.63e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—HRAS—thyroid cancer	9.94e-06	6.43e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—TP53—thyroid cancer	9.86e-06	6.38e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—HRAS—thyroid cancer	9.43e-06	6.1e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTGS2—thyroid cancer	9.26e-06	6e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTGS2—thyroid cancer	9.24e-06	5.98e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—NRAS—thyroid cancer	9.14e-06	5.92e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PPARG—thyroid cancer	9.09e-06	5.88e-05	CbGpPWpGaD
Thalidomide—NFKB1—Signaling Pathways—AKT1—thyroid cancer	8.78e-06	5.68e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTGS2—thyroid cancer	8.73e-06	5.65e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—PTEN—thyroid cancer	8.58e-06	5.55e-05	CbGpPWpGaD
Thalidomide—FGFR2—Signaling Pathways—AKT1—thyroid cancer	8.33e-06	5.39e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PPARG—thyroid cancer	8.28e-06	5.36e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—PTEN—thyroid cancer	8.08e-06	5.23e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—PTEN—thyroid cancer	8.06e-06	5.22e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—KRAS—thyroid cancer	7.87e-06	5.09e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—PTEN—thyroid cancer	7.62e-06	4.93e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTGS2—thyroid cancer	7.15e-06	4.63e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PPARG—thyroid cancer	7.08e-06	4.58e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—HRAS—thyroid cancer	6.69e-06	4.33e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTGS2—thyroid cancer	6.52e-06	4.22e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—PTEN—thyroid cancer	6.23e-06	4.03e-05	CbGpPWpGaD
Thalidomide—PTGS1—Metabolism—AKT1—thyroid cancer	6.23e-06	4.03e-05	CbGpPWpGaD
Thalidomide—PTGS2—Disease—AKT1—thyroid cancer	5.91e-06	3.82e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—PTEN—thyroid cancer	5.68e-06	3.68e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTGS2—thyroid cancer	5.57e-06	3.6e-05	CbGpPWpGaD
Thalidomide—PTGS2—Metabolism—AKT1—thyroid cancer	4.95e-06	3.2e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—PTEN—thyroid cancer	4.86e-06	3.14e-05	CbGpPWpGaD
Thalidomide—CYP2E1—Metabolism—AKT1—thyroid cancer	4.66e-06	3.01e-05	CbGpPWpGaD
Thalidomide—CYP3A5—Metabolism—AKT1—thyroid cancer	4.65e-06	3.01e-05	CbGpPWpGaD
Thalidomide—CYP1A1—Metabolism—AKT1—thyroid cancer	4.39e-06	2.84e-05	CbGpPWpGaD
Thalidomide—CYP2C19—Metabolism—AKT1—thyroid cancer	3.59e-06	2.32e-05	CbGpPWpGaD
Thalidomide—CYP2C9—Metabolism—AKT1—thyroid cancer	3.28e-06	2.12e-05	CbGpPWpGaD
Thalidomide—CYP1A2—Metabolism—AKT1—thyroid cancer	2.8e-06	1.81e-05	CbGpPWpGaD
